PUBLIC COMPANY
saveNovo Nordisk Inc
updated 5mo ago
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval78 co-mentions · 39 sources
- drugVICTOZA59 co-mentions · 30 sources
- drugLIRAGLUTIDE30 co-mentions · 30 sources
- drugSaxenda30 co-mentions · 30 sources
- drugOzempic23 co-mentions · 4 sources
- drugWegovy23 co-mentions · 4 sources
- drugWegovy Pill22 co-mentions · 3 sources
- drugSOGROYA18 co-mentions · 9 sources
pipeline
16
marketed
15
phase 3
0
catalysts ytd
4
approvals ytd
3
recalls ytd
0
Pipeline(16)
view full pipeline →pipeline depth16 products
15Marketed1Unknown
Marketed
(estradiol + norethindrone)
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/…
Marketed(insulin aspart + insulin aspart protamine)
Type 1 Diabetes (Juvenile Diabetes)
Marketed(insulin degludec + liraglutide)
Type 2 Diabetes
Marketed(insulin human + insulin isophane)
Type 1 Diabetes (Juvenile Diabetes)
MarketedFiasp
Type 1 Diabetes (Juvenile Diabetes)
MarketedRybelsus
Cardiovascular Risk Factors
MarketedSaxenda
Obesity
MarketedWegovy Pill
type 2 diabetes, cardiovascular risk reduction
Marketedcoagulation factor IX (recombinant), glycopegylated LA
Hemophilia B (Factor IX Deficiency)
Marketedcoagulation factor XIII A-subunit (recombinant)
Fibrin Stabilizing Factor Deficiency (Factor XIII Deficie…
Marketedconcizumab
Hemophilia A (Factor VIII Deficiency)
Marketeddasiglucagon
Hypoglycemia
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesityHow obesity medications may become the next big battleground over access to medicines in lower-income countries.stat · 17h ago
- AstraZeneca, Calidi, Tempest make significant workforce cutsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 17h ago
- Novo’s CagriSema drives more than 20% weight loss at lower dosesAs Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…biospace · 20h ago
- Their loss, our gain? Canada makes its case to Europe amid U.S. instabilityCompanies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.biospace · 21h ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 3d ago
- Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera assetWith 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.biospace · 4d ago
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye diseaseTwelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.biospace · 7d ago
- Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 injectable Zepbound secured the first approval in the space in December 2024.biospace · 7d ago
- STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionThe FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."stat · 7d ago
- Merck’s MASH hopeful efinopegdutide wins in mid-stage studyMerck & Co. revealed results from a mid-stage clinical trial showing its GLP-1 and glucagon receptor co-agonist efinopegdutide resolved cases of MASH compared with placebo without worsening liver f…fiercebiotech · 7d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that